Compare Elastic NV (ESTC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Vertex Pharmaceuticals Incorporated — how do they compare? Elastic NV trades at $61.95 (market cap $6.47B), while Vertex Pharmaceuticals Incorporated trades at $480.61 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.7× Elastic NV's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Elastic NV nearer its low. Which is the better fit depends on your goals.
| ESTC | VRTX | |
|---|---|---|
Market Cap | $6.47B | $121.09B |
Sector | Technology | Health |
52-Week High | $94.47 | $529.59 |
52-Week Low | $43.30 | $366.54 |
Enterprise Value | $5.69B | $115.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic N.V. (ESTC) trades at $61.75, down 0.91% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust revenue growth, reaching $1.48B in 2025 with expectations of $1.7B in 2026, and has consistently beaten EPS estimates in recent quarters. Recent positive news includes Elastic Security achieving a 100% malware protection score and being named a Leader in IDC MarketScape's SIEM 2026 assessment.
Wall Street maintains a bullish outlook with 23 buy ratings and a $73 consensus price target, representing 18% upside. However, investors should note the high EV/EBITDA ratio of 164.13 and ongoing legal investigations highlighted in recent news. The stock's current RSI levels suggest potential overbought conditions, while strong profitability metrics and institutional support provide fundamental backing.
Vertex Pharmaceuticals (VRTX) trades at $476.31, down 0.82% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.47, and maintains robust profitability with a net income margin of 35.51%. Recent news highlights a $10 billion acquisition of Crinetics Pharmaceuticals, aimed at expanding its endocrinology portfolio with potential peak sales of over $5 billion.
The outlook remains positive with analyst consensus favoring a buy rating (83.92%) and a price target of $538, suggesting 13% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments, while strong cash flow and earnings growth support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
